Dog & Cat Vaccines

Active immunisation of cats aged 8 weeks and older against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs and viral excretion; against Chlamydophila felis infection to reduce clinical signs; and against feline panleucopenia to prevent mortality and reduce clinical signs. Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components. The duration of immunity is 1 year after the last (re)vaccination for rhinotracheitis, calicivirus, and Chlamydophila felis, and 3 years for panleucopenia component. Dosage and administration 1 ml by subcutaneous injection after reconstitution of the freeze-dried pellet with the solvent, according to the following schedule: Primary vaccination: First injection: from 8 weeks of age, Second injection: 3 to 4 weeks later. Revaccination: For all components one year after the primary vaccination course, then every year for the rhinotracheitis, calicivirosis and chlamydiosis components, and every three years for the panleucopenia component. Where high levels of maternal antibodies against R, C, P or Ch components are expected to be present (e.g. in kittens of 9 - 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

Active immunisation of cats aged 8 weeks and older against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs and viral excretion; against feline panleucopenia to prevent mortality and reduce clinical signs; and against feline leukaemia to prevent persistent viraemia and reduce clinical signs of the disease. Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. The duration of immunity is 1 year after the last (re)vaccination for rhinotracheitis, calicivirus and feline leukaemia components, and 3 years for panleucopenia component. Dosage and administration 1 ml by subcutaneous injection after reconstitution of the freeze-dried pellet with the solvent, according to the following schedule: Primary vaccination: First injection: from 8 weeks of age, Second injection: 3 to 4 weeks later. Revaccination: For all components one year after the primary vaccination course, then every year for the rhinotracheitis, calicivirosis and feline leukaemia components, and every three years for the panleucopenia component. Where high levels of maternal antibodies against R, C or P components are expected to be present (e.g. in kittens of 9 - 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

For the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection. Immunity has been demonstrated 1 month after vaccination and has been shown to persist up to the next re-vaccination dose. Dosage and administration Inject one 1 ml dose subcutaneously, according to the following schedule: Minimum age at vaccination: 3 months. Booster vaccination should be given every two years.

For the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection. Immunity has been demonstrated 1 month after vaccination and has been shown to persist up to the next re-vaccination dose. Dosage and administration Inject one 1 ml dose subcutaneously, according to the following schedule: Minimum age at vaccination: 3 months. Booster vaccination should be given every two years.

For the active immunisation of healthy puppies and dogs to prevent mortality and clinical signs due to canine distemper virus infections, to prevent clinical signs and reduce infection or excretion due to canine parvovirus infections, to reduce mortality and clinical signs due to canine adenovirus type 1 infections, to reduce clinical signs and infection or excretion due to canine adenovirus type 2 infections, to reduce clinical signs and infection due to Leptospira canicola and icterohaemorrhagiae, and to reduce pathological signs of disease caused by canine parainfluenzavirus infections. Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Scheme. The duration of immunity for canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2 and the leptospiral components is at least 12 months. However, the duration of immunity for canine parainfluenzavirus has not been determined. Dosage and administration Reconstitute one vial of the freeze-dried fraction (Vanguard DA2Pi) aseptically using the contents of one vial of the liquid fraction (Vanguard CPV-L) as diluent. Shake well and immediately inject the entire contents of the reconstituted vial (1 ml) subcutaneously. Do not use chemically sterilized syringes or needles, as these will interfere with the effectiveness of the vaccine. Basic Vaccination Scheme: Puppies younger than 10 weeks of age: Two doses of Vanguard 7 at least 14 days apart. The first dose can be given as young as 7 weeks of age. The second dose should not be given until at least 10 weeks of age. Puppies 10 weeks of age and older: A single dose of Vanguard 7, followed by a single dose of Vanguard Lepto ci at least 14 days later. Booster Vaccination: Leptospiral components – annual booster vaccination is recommended. Viral components – annual booster vaccination is recommended. However, should Veterinary Surgeons conduct a risk-benefit analysis for individual animals to determine the frequency of revaccination with Vanguard 7, they should be aware of the following information. Serological data has indicated that most dogs, when given at least the first annual booster, can maintain protective levels of immunity to the viral components of Vanguard 7 for up to 4 years.

For the active immunisation of healthy puppies and dogs to prevent clinical signs and reduce infection or excretion due to canine parvovirus. Onset of immunity occurs by approximately 2 weeks after the last dose of the Basic Vaccination Scheme. The duration of immunity is at least 12 months. Dosage and administration Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously. Do not use chemically sterilized syringes or needles, as these will interfere with the effectiveness of the vaccine. Basic Vaccination Scheme: Puppies younger than 10 weeks of age: Two doses of Vanguard CPV at least 14 days apart. The first dose can be given as young as 6 weeks of age. The second dose should not be given until at least 10 weeks of age. Puppies 10 weeks of age and older: A single dose of Vanguard CPV. Booster Vaccination: Annual booster vaccination is recommended.

Active immunisation of dogs from 6 weeks of age to prevent mortality, clinical signs and reduce viral shedding caused by canine parovirus and to reduce infection caused by Leptospira canicola and Leptospira icterohaemorrhagiae. 1ml by subcutaneus injection.

For active immunisation of dogs from 6 weeks of age to reduce infection caused by Leptospira canicola and Leptospira icterohaemorrhagiae. 1ml subcutaneous injection. VPA 10019/074/001. Active ingredient: Inactivated Leptospira canicola, Leptospira icterohaemorrhagiae

Active immunisation of dogs from 8 weeks of age: •to reduce clinical signs and excretion following infection with Bordetella bronchiseptica. Onset of immunity - 3 weeks. Duration of immunity - 12 months. Primary vaccination scheme Vaccination with 1 dose of 1 ml per dog from the age of 8 weeks. Re-vaccination scheme One dose annually.

Versican Plus BbPi IN nasal drops lyophilisate and solvent for suspension for dogs. Active immunisation of dogs from 3 weeks of age:- to reduce clinical signs and bacterial excretion after infection with Bordetella bronchiseptica and - to reduce clinical signs and viral excretion after infection with canine parainfluenza virus.

Active immunisation of dogs from 6 weeks of age: - to prevent mortality and clinical signs caused by canine distemper virus, - to prevent mortality and clinical signs caused by canine adenovirus type 1, - to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2, - to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus, - to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus, - to prevent clinical signs, infection and urinary excretion caused by L.interrogans serogroup Australis serovar Bratislava, - to prevent clinical signs and urinary excretion and reduce infection caused by L.interrogans serogroup Canicola serovar Canicola and L.interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, - to prevent clinical signs and reduce infection and urinary excretion caused by L.kirschneri serogroup Grippotyphosa serovar Grippotyphosa. Onset of immunity - 3 weeks after the first vaccination for CDV, CAV, CPV. - 3 weeks after completion of the primary course for CPiV and - 4 weeks after completion of the primary course for Leptospira components. Duration of immunity At least three years following the primary vaccination course for CDV, CAV-1, CAV-2 and CPV. The duration of immunity against CAV-2 was established by serology. At least one year following the primary vaccination course for CPiV and Leptospira components. Primary vaccination scheme Two doses of Versican Plus DHPPi/L4 3–4 weeks apart from 6 weeks of age. Re-vaccination scheme A single dose of Versican Plus DHPPi/L4 can be given every 3 years. Annual re-vaccination is required for parainfluenza and Leptospira components; therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.

Active immunisation of dogs from 6 weeks of age: -to prevent mortality and clinical signs caused by canine distemper virus, -to prevent mortality and clinical signs caused by canine adenovirus type 1, -to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2, -to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus, -to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus, -to prevent clinical signs, infection and urinary excretion caused by L.interrogans serogroup Australis serovar Bratislava, -to prevent clinical signs and urinary excretion and reduce infection caused by L.interrogans serogroup Canicola serovar Canicola and L.interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, -to prevent clinical signs and reduce infection and urinary excretion caused by L.kirschneri serogroup Grippotyphosa serovar Grippotyphosa. Onset of immunity -3 weeks after the first vaccination for CDV, CAV, CPV. -3 weeks after completion of the primary course for CPiV and -4 weeks after completion of the primary course for Leptospira components. Duration of immunity At least three years following the primary vaccination course for CDV, CAV-1, CAV-2 and CPV. The duration of immunity against CAV-2 was established by serology. At least one year following the primary vaccination course for CPiV and Leptospira components. Dose and route of administration Aseptically reconstitute the lyophilisate with the suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product subcutaneously. Primary vaccination scheme Two doses of Versican Plus DHPPi/L4 3–4 weeks apart from 6 weeks of age. Re-vaccination scheme A single dose of Versican Plus DHPPi/L4 can be given every 3 years. Annual re-vaccination is required for parainfluenza and Leptospira components; therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.